

CLAIM AMENDMENTS

1. (canceled)

2. (currently amended) ~~DNAzymes according to claim 1~~
~~characterized in that they comprise~~ A DNAzyme which binds to
GATA-3 mRNA and functionally inactivates it, which comprises:

- a catalytic domain with the nucleotide sequence
GGCTAGCTA CA AC GA or a modified sequence with comparable biological
effect, which cleaves the GATA-3 mRNA at every
purine:pyrimidine binding site to which it is bonded,

- a right substrate binding domain adjoining the 3' end
of the catalytic domain and

- a left substrate binding domain adjoining the 5' end of
the catalytic domain, both substrate binding domains being respectively
complementary to two regions of the GATA 3 mRNA so that they
hybridize with the mRNA, and

- ~~[[are]]~~ which is active in vivo.

3. (currently amended) ~~DNAzymes~~ A DNAzyme according to
claim 2, ~~characterized in that they comprise~~ which comprises the
sequence hgd 40 GTGGATGGA GGCTAGCTACAACGA GTCCTTGGAG.

1 4. (currently amended) ~~DNAzymes~~ A DNAzyme according to
2 claim 2 ~~the claims 2 and 3, characterized in that they cleave which~~
3 cleaves the catalytic domain of the GATA-3 mRNA at every purine:
4 uracil binding site.

1 5. (currently amended) ~~DNAzymes~~ A DNAzyme according to
2 claim 2 ~~claims 2 to 4, characterized in that they are which is~~
3 stabilized against decomposition within the organism by ~~[[the]]~~
4 introduction of a 3'-3' inversion.

1 6. (currently amended) ~~DNAzymes~~ A DNAzyme according to
2 claim 2 ~~claims 2 to 5, characterized in that they are which is~~
3 stabilized against decomposition within the organism by ~~[[the]]~~
4 introduction of modified nucleotides or nucleotide compounds.

1 7. (currently amended) ~~DNAzymes~~ A DNAzyme according to
2 claim 2 ~~claims 2 to 6, characterized in that they present as~~
3 modification which includes an inverse thymidine on the 3' end
4 and/or a FAM label on the 5' end.

1 8. (currently amended) ~~Medicament~~ A medicament contain-
2 ing a DNAzyme according to ~~the claims 2 to 7~~ claim 2 and a pharma-
3 ceutically acceptable carrier.

Claims 9 through 16 (canceled).